New Drug Approvals (Original) — August 18, 2026
This digest covers 5 FDA approvals from August 13-14, 2026, comprising 2 NMEs and 3 biosimilars, with no label expansions. The dominant therapeutic area signal is oncology, driven by Bristol Myers Squibb's iberdomide (ZENBEXUS) NME approval with Priority Review and Orphan Drug designations for a NOT_DISCLOSED indication, representing the highest-conviction bullish event. Cerveau Technologies' florquinitau F18 (TAUKLARIFY) NME approval for tau PET imaging in Alzheimer's disease is a second bullish signal, addressing a critical diagnostic gap. The three biosimilar approvals—pitolistant from Lupin and MSN Laboratories, and fidaxomicin from Sandoz—are neutral events with no disclosed originator or market size data, limiting competitive analysis. Key watch items include iberdomide's commercial launch execution and payer coverage for a novel oncology agent, and florquinitau F18's market adoption in a nascent diagnostic space.